Accesswire 18-Jul-2017 9:00 AM
LAS VEGAS, NV / ACCESSWIRE / July 18, 2017 / Neutra Corp. (OTCQB: NTRR) is excited about future business prospects, noting that half of the fifty states plus the District of Columbia now have laws in place legalizing cannabis in at least some form - either for medicinal and/or recreational use. This growing trend towards legalization and acceptance bodes well for NTRR's antimicrobial solutions, which mitigate the often-harsh chemicals used at cannabis farms to aid plant growth.
Currently, eight states allow for recreational consumption (up from just two in 2012), 21 permit use for medicinal purposes only, and five have legalized both recreational and medicinal use.
"We've crossed an important threshold as an industry," said NTRR CEO Chris Brown. "Half of the states now permit cannabis use in some form. The momentum is now on our side. Market conditions are becoming ever more favorable for our business. With more states allowing for use, more cannabis farms will be started to meet that demand, resulting in more customers for our antimicrobial solutions."
Demand in the legalized cannabis market is now growing so rapidly, some experts predict it will become a $70 billion industry by 2020. Others believe the legalized cannabis industry could soon overtake the nation's manufacturing sector in job creation. Legalized cannabis already far outstrips Viagra and Cialis, music streaming and tequila in actual sales, and the total estimated demand (including demand in states where cannabis is not yet approved for use), trails only beer and cigarettes in potential retail sales.
NTRR is hard at work marketing and promoting new, antimicrobial alternatives to harsh chemicals used in cannabis farms. NTRR plans to continue to source out solutions for cannabis producers and consumers alike as the regulated cannabis industry continues to swell in the United States, Canada and beyond. For more information on the company's mission, please visit http://neutrainc.com/investors.
About Neutra Corp.
As the global cannabis market grows exponentially, it is constantly in need of better technologies and products to be more efficient in how they grow, what they grow, and how they consume cannabis and its related products. From lighting to dosage devices, from pesticide replacements to plant enhancers, NTRR is constantly combing the industry for the latest and greatest to test, prove and bring to market.
By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (GWPH), Cara Therapeutics Inc. (CARA) and 22nd Century Group, Inc. (XXII). For investing information and performance data, please visit www.neutrainc.com.
Notice Regarding Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Neutra Corp. Chris Brown, 813-367-2041 President and CEO firstname.lastname@example.org
SOURCE: Neutra Corp.
Limited Time Offer:
Claim your free copy of income expert Bryan Perry's new report:
My Top Monthly Dividend Payer (8% Dividend Yield)
You'll also receive Bryan Perry's weekly e-letter, Dividend Investing Weekly, at no cost, along with other associated financial content and special offers.